Indications
Yuvanci is indicated as substitution therapy for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, who are already treated with the combination of macitentan and tadalafil given concurrently as separate tablets.
Composition
- Active substance
- macitentan, tadalafil
- International name (INN)
- macitentan;tadalafil
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Yuvanci
- Active substance
- macitentan, tadalafil
- ATC code
- C02KX54
- Therapeutic area
- Pulmonary Arterial Hypertension